Cell And Gene Therapy Innovations

Eli Lilly and Company just dropped $1.3 billion to turn off a gene. Permanently. Not suppress. Not modulate. Not block. One edit. One time. And PCSK9 is gone. That may sound like science fiction. But it is not. This week, Eli Lilly announced its acquisition of Verve Therapeutics (a biotechnology company developing a new kind of medicine). It is not a pill. It is not an injection you take every week. It is a one-time treatment that edits your DNA. The therapy is called Verve 102. It targets a gene known as PCSK9, which plays a key role in regulating cholesterol. Specifically LDL, the so-called “bad” cholesterol that contributes to heart disease. Scientists found that by changing a single letter in that gene (literally one letter in your genetic code), they can shut it down. When that happens, LDL levels drop. In early human trials, a single dose lowered LDL by more than 50 percent. That is not just comparable to the best drugs we have today… it might actually outperform them. And again, it is one treatment. For life. This kind of gene editing is called base editing. It does not cut your DNA like older CRISPR tools. Instead, it rewrites a single base (an A to a G) with extraordinary precision. The edit happens in the liver, where cholesterol is processed, using a delivery system designed to find the right cells and make the change. Why does this matter? Because for the first time, we are not just managing high cholesterol. We are looking at the possibility of removing the root cause… with one carefully targeted edit. And Eli Lilly just staked $1.3 billion on it. If successful, this could mark the beginning of a new era in medicine. One where chronic conditions like high cholesterol are not treated with decades of pills but with a single genetic correction that rewrites the story from the start. It is early. The trials are still underway. But this is a moment worth watching. Because the question now is not just can we edit our genes…

BIG News for Cell Therapy Patients: FDA today eases CAR-T restrictions 👇 The FDA has approved label updates for BMS’ CAR-T therapies Abecma and Breyanzi, removing REMS requirements and reducing post-treatment monitoring obligations. This matters. Only about 20% of eligible patients in the U.S. currently receive CAR-T therapy. This isn’t due to clinical reasons - it’s because many patients and their families face the harsh reality of traveling hours, sometimes across state lines, to reach certified treatment centres. A quietly significant shift in cell therapy access? Key changes: • REMS removal - reflecting that healthcare systems are now better equipped to manage key safety risks (CRS, ICANS) without extra regulatory hurdles • Monitoring reduction post-treatment proximity window cut from 4 weeks to 2 • Driving restrictions reduced from 8 weeks to 2 weeks. These updates can help shift CAR-T from a complex, limited-access treatment to one that’s available sooner and closer to home, including at select community hospitals. Community is key. Because no patient or family should have to drive hours or relocate for life-saving treatment. More patients. Sooner. Closer to home 👏 #celltherapy #oncology #CGTweekly #cellandgenetherapy

FUTURE TRENDS IN CELL AND GENE THERAPY (2026–2030): CRISIS, OPPORTUNITY OR BOTH?/ After a turbulent 2024–25, I kept getting the same question: where does cell & gene therapy go next? This position paper tries to summarize a pragmatic roadmap for founders and investors. Our perspective is informed by recent experience, including our exit from Esobiotec (acquired by AstraZeneca). Thesis: The next five years will be shaped by four forces — in vivo delivery, cost curves (CMC), access policy, and China — with AI powering design, manufacturing, and clinical execution. From 2026 onward, expect fewer but “shocking” wins that reset expectations. What’s changing: ● From hype to hard problems. CAR‑T and gene therapy delivered real cures, now the frontier is solid tumors, larger genes, and scalable delivery. ● In vivo moves center stage. Recent landmark deals signal that editing or programming cells inside the body will define the next platform wave. ● Cost curves bend. Rapid CAR‑T (7–10 days), point‑of‑care manufacturing, and automated QC turn CMC into a core moat. ● Access vs. innovation finds rules. Hospital exemptions and right‑to‑try expansions will force clearer coexistence between academic access and commercial pathways. ● China changes the price and pace. Massive trial volume and lower costs put global pressure on CGT pricing, and open new cross‑border development routes. ● AI becomes non‑optional. From target and capsid design to bioreactor control and trial ops, AI is now a competitive baseline. Investor playbook 1️⃣ Back delivery (in vivo & non‑viral): the platforms that scale beyond bespoke products. 2️⃣ Build CMC + data moats: speed, reliability, and AI‑driven manufacturing as first‑order strategy. 3️⃣ Globalize early, design for access: partner with leading hospitals, plan China/EU routes, and align incentives (outcomes‑based models). Inside the paper you’ll find a 1‑page landscape map (p.1), a deal & signal table (p.9), and concrete takeaways for teams navigating the next cycle. 👉 Download/print the full paper: https://lnkd.in/dqzZX7ZX #celltherapy #genetherapy #biotech #venturecapital #AIinBiotech #CMC

A #Breakthrough Year for T Cells This year has been transformative for T cell therapies in the fight against cancer, as reviewed by Rigel Kishton and me in today’s issue of Nature Cancer (https://rdcu.be/d3R8D). With three FDA approvals, 2024 has underscored the clinical power of #Tcells -- living #immunotherapies capable of achieving results where all other treatments fail. Key Approvals of 2024 -> #Lifileucel (Amtagvi): The first #TIL-based therapy for unresectable/metastatic melanoma, approved in February. -> Afamitresgene (Tecelra): The first #TCR-engineered therapy for solid tumors, approved in August for synovial sarcoma. -> Obecabtagene (Aucatzyl): The 7th #CAR T therapy for B cell hematologic malignancies, approved last month. 🚀 These therapies are clinically remarkable. Engineered from a patient’s own T cells, they deliver life-changing responses for patients with no other options. I’ve had the privilege of contributing to these advancements and witnessing their profound impact. The Promise of TIL Therapies TIL-based therapies hold transformative potential. By recognizing tumor #neoantigens -- expressed #mutations, cancer germline antigens, and even “#darkgenome” products like #HERVs or #pseudogenes -- T cells can achieve durable, complete responses. CD4+ and CD8+ T cells bring the ability to directly or indirectly eliminate tumors where traditional therapies fall short. Despite these advances, the oncology capital markets remain skeptical. Cell therapy companies face immense challenges: -> Development Costs: Complex manufacturing, high trial expenses, and stringent regulations. -> Safety Concerns: Risks like cytokine release syndrome and lymphodepletion-associated toxicities. -> Commercialization Hurdles: High prices, uncertain reimbursement, and cumbersome logistics. The result? T cell-based immunotherapies can land with a thud from investors concerned about small target markets and costly treatment delivery. ⚡ Technology as a Solution The future of T cell-based therapies looks brighter with technological innovation: -> #AI/ML for Transcriptomics and Genomics: Personalizing T cell products for individual patients. -> Cheaper #Sequencing: Accelerating tumor neoantigen target discovery. -> Improved Culture Methods: Enhancing T cell #stem cell qualities for durable efficacy. While #Tcellengagers and #bispecificantibodies gain investor interest for their transient solid tumor activity, these treatments are rarely curative. TIL therapies, on the other hand, stand on the cusp of delivering transformative, long-term responses in patients with common solid tumors. The journey isn’t easy—financial skepticism, logistical hurdles, and scientific complexity remain—but the horizon for T cell therapies is filled with extraordinary possibility. Here’s to the progress we've made and the breakthroughs that lie ahead. 🎇 #immunotherapy #celltherapy #carT #TIL #oncology

🚨 FDA Just Tore Down a Major Barrier to CAR-T Access 🚨 Big win for cancer care. Even bigger win for patients. This week, the FDA removed REMS restrictions on ALL currently approved BCMA and CD19 CAR-T therapies, a move that could double uptake across the U.S. Here’s what’s changing: ✅ No more REMS certification needed for hospitals ✅ No more 4-week post-treatment monitoring at certified centers ✅ No more 8-week driving restriction (now 2 weeks) ✅ Patients only need to stay near a care facility for 2 weeks post-infusion 💥 The result? • Easier access for rural patients • Less burden on oncology centers • More community cancer sites offering CAR-T Impacted therapies: 🧬 Abecma (BMS) 🧬 Breyanzi (BMS) 🧬 Yescarta, Tecartus (Gilead) 🧬 Carvykti (J&J/Legend) 🧬 Kymriah (Novartis) Industry analysts say this could unlock stagnant market penetration — especially for CD19 CAR-Ts in lymphoma. 💭 CAR-T has long been limited by logistics, not just science. This move brings us a step closer to making curative immunotherapies more mainstream. ��� If you're in biotech, commercial strategy, validation, or clinical operations, what does this mean for site readiness, CMO scale-up, or decentralization? Let’s talk. 🔔 I post weekly on life sciences trends, immunotherapy shifts, and pharma talent across the U.S. #CART #FDA #Immunotherapy #GeneTherapy #BiotechNews #Oncology #RegulatoryAffairs #Biologics #CancerResearch #LifeSciences #PharmaOps #ClinicalTrials #PharmaNews #Validation #CD19 #BCMA #CellTherapy #PatientAccess

My billion-dollar question in regenerative medicine: Why are we still drilling into people's bones for stem cells? 🤔 The biggest bottleneck in advancing MSC-based therapies is the limited, invasive, and inconsistent sources from which we currently obtain mesenchymal stem/stromal cells (MSCs). 1/ Current MSC sources are invasive and scarce. Bone marrow extraction is painful and yields low cell counts. Adipose tissue requires surgery and shows huge variability between donors. This limits how many donors participate and drives up cost and complexity. 2/ Donor variability disrupts consistency. MSC quality varies with donor age and health. Older donors’ cells have lower regenerative potential, making it hard to get large batches of uniform, effective cells for therapies. 3/ Isolation and expansion are slow and costly. Extracting MSCs takes hours of lab work, and growing enough cells for clinical use takes weeks, during which cells can lose their potency. Plus, strict contamination controls and GMP regulations add complexity and expense. Menstrual blood-derived MSCs (MenSCs) can bridge the gap Menstrual blood offers a game-changing alternative: a non-invasive, easily accessible, and repeatable source of MSCs with high yield potential. Collecting MenSCs regularly from healthy donors means: • No painful procedures boost donor willingness • More consistent, renewable stem cell supply • Faster, scalable sourcing to meet clinical demands At Muse Bio, we’re pioneering this innovative approach to unlock a more efficient, scalable, and patient-friendly path for regenerative therapies, overcoming the bottlenecks that have held the field back for too long. Let's give these cells a second chance to create future regenerative therapies.

Breakthrough gene therapy lets children and young adults hear again, offering real hope for curing deafness A gene therapy has restored hearing in toddlers, teens, and young adults with OTOF-related deafness, caused by mutations in the OTOF gene that prevent the inner ear from sending sound signals to the brain. Their hearing structures remain intact, but the missing otoferlin protein keeps them from hearing. Doctors used a harmless virus to deliver a working copy of the OTOF gene into the ear’s hair cells. This enabled the cells to produce otoferlin, allowing sound signals to reach the brain. In a trial involving patients aged 1 to 24, hearing improved within weeks, with brain tests showing an average 62% gain and behavioral tests 78%. Two participants reached near-normal speech perception. Side effects were mild, mainly brief drops in white blood cell counts. Children aged five to eight showed the greatest improvement, though the reason remains unclear. RESEARCH PAPER 📄 DOI: 10.1038/s41591-025-03773-w

A Long Island man has become the first person in New York state to be cured of sickle cell anemia. For 21 years, Sebastien Beauzile lived with the constant pain and complications of sickle cell disease, a disorder where red blood cells become crescent-shaped and clog blood vessels, causing pain, fatigue, organ damage, and a shortened life span. But at Cohen Children’s Medical Center, he received a cutting-edge therapy that’s offering new hope to thousands living with the same disease. The treatment, called Lyfgenia, works by extracting a patient’s own bone marrow stem cells, genetically modifying them in the lab, and infusing them back into the body. These altered cells then produce healthy red blood cells, reducing or even eliminating the sickling effect. For Beauzile, the transformation was profound. His chronic pain vanished. His blood began flowing freely. He could walk, travel, even dream again. “Sickle cell was like a blockade,” he said. “But now it’s just a wall I jumped over.” Sickle cell disease was first described in 1910. For over a century, patients have relied on treatments that manage symptoms but don’t cure the disease. This therapy represents something different: a one-time genetic fix that rewrites how the body makes blood. The condition primarily affects people of African, Mediterranean, and Middle Eastern descent. Doctors at Cohen Children’s hope this therapy will now reach communities long overlooked in clinical innovation. Gene therapy isn’t risk-free. It’s intensive, expensive, and still being studied in larger trials. But for the first time, a cure is within reach – not just for one patient, but potentially for many. Learn more: “Long Island man is first in New York history to be cured of sickle cell anemia.” CBS New York, 2025.